The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor activator , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist https://bookmarkusers.com/story21436889/retatrutide-and-nad-a-triple-threat-approach-to-metabolic-wellness